Apex Scientific

21+ access.
Research use only.

Before entering, confirm that you meet the age requirement and understand the research-use limitations that apply to every Apex product.

If provided, your email can be carried into checkout for convenience. It is not required to browse and does not subscribe you to marketing. Read the Privacy Notice, Research Use Policy, and Terms.

Leave site

Your acknowledgement is remembered on this device for 30 days.

Research use only Clear product information Free shipping on orders over $200 20% launch offer · Use code APEX101
Apex Scientific
SearchBag

Compound guide

PT-141

A pathway-focused guide to molecular mechanisms, published evidence, and the limits of interpretation.

Overview

A Summary:PT-141

PT-141 is the research name for bremelanotide, a cyclic peptide that activates several melanocortin receptor subtypes.

It is used to study central melanocortin signaling, particularly pathways involving MC4 receptors in the central nervous system.

An FDA-approved bremelanotide medicine exists with a specific formulation and indication. That approval does not extend to this research vial or make it suitable for self-administration.

Research model

Cellular & MolecularHow PT-141 Is Studied

These receptors, enzymes, and signaling networks define the primary laboratory questions associated with this research material.

01Central motivation pathway

Melanocortin-4 receptor

At the cellular or molecular level

Bremelanotide activates melanocortin receptors, with MC4 receptor signaling considered important to its central effects. These G-protein-coupled receptors can alter neuronal cyclic-AMP signaling.

02Behavioral integration

Hypothalamic + limbic circuits

At the cellular or molecular level

Melanocortin signals are integrated across hypothalamic and limbic regions that combine hormonal state, reward, attention, and autonomic response.

03Tolerability pathways

Peripheral melanocortin effects

At the cellular or molecular level

Melanocortin receptors and connected autonomic pathways can affect nausea, flushing, blood pressure, heart rate, and pigmentation-related biology.

Research interpretation

How to read the pathway.

01

Central motivation pathway

Bremelanotide activates melanocortin receptors, with MC4 receptor signaling considered important to its central effects.

02

Behavioral integration

Melanocortin signals are integrated across hypothalamic and limbic regions that combine hormonal state, reward, attention, and autonomic response.

03

Tolerability pathways

Melanocortin receptors and connected autonomic pathways can affect nausea, flushing, blood pressure, heart rate, and pigmentation-related biology.

Evidence boundary

An FDA-approved bremelanotide medicine exists with a specific formulation and indication. That approval does not extend to this research vial or make it suitable for self-administration.

Read the evidence

Sources BehindThis Guide

FDA bremelanotide mechanism and labeling (opens in a new tab)RECONNECT phase 3 trials (opens in a new tab)Bremelanotide (PT-141) identity record (opens in a new tab)

One important note

Educational Notice

Two phase 3 trials studied a specific bremelanotide formulation in premenopausal women with hypoactive sexual desire disorder. Nausea, flushing, and headache occurred more often than with placebo.

This guide summarizes molecular mechanisms, published evidence, and evidence limits in everyday language. It is educational information, not medical advice or instructions for personal use. Products offered on this site are intended exclusively for laboratory research and are not for human or veterinary use.